Recent years have shown a rise in development across the generic and biosimilar industries, as many blockbuster products near the end of their patents. The need to expand the reach of R&D programmes has driven major new investments in co-development, strategic alliances, licensing and acquisitions, with big pharmaceutical companies scrambling to maintain their strongholds in specific therapeutic areas. This has increased the need for a robust due diligence process across all functions, as companies look to external targets as a means of supplementing pipelines and bolstering their product portfolios.
With the rising costs of drug and device reviews and the uncertainty of FDA approvals, the prospect of developing a new product from discovery onward has become a highly risky endeavour. Therefore, conducting strategic
due diligence to identify and integrate potential targets at a stage of assured success, though costly, can often be an efficient approach to supplement organic business development.
Over the last four years, our US-based conference has provided
due diligence professionals with a platform to explore innovative models and deal structures for collaborating with strategic partners, and discussed valuable strategies for conducting efficient and effective due diligence. Join your peers at the inaugural
European Due Diligence Summit for Life Sciences for the opportunity to network and engage with some of the industry's leading experts.
Top Five Reasons to Attend
- Explore best practices for companies of all sizes looking to acquire or in-license a product
- Understand how to conduct a comprehensive intellectual property due diligence investigation, and how it can alter the strategy for your deal
- Learn how to evaluate and effectively manage strategic alliances through case studies from industry leaders
- Assess the regulatory and compliance standards of a target and how gaps can lead to unforeseen financial burdens
- Gain valuable insight on the impact company culture can have on the success of integrating the workforce post-merger or acquisition
Speakers
- Gareth Ayre, Head Centre of Excellence, Due Diligence, NOVARTIS
- Robert Bauer, Ph.D., Director, Business Development EMEA, SANTEN
- Marco Cerato, Head of BD&L, Late-Stage and Marketed Products, HELSINN
- Nick Clarke, Ph.D., Head of U.K. Academic Partnerships, External Science and Innovation, PFIZER
- Chris Davie, Executive Director, Diligence, MUNDIPHARMA
- Austin Doyle, Ph.D., FRSB, Director, Science and Technology Licensing, R&D Worldwide Business Development, GSK
- John Easton, Ph.D., Head of Business Operations, Business Development, ASTRAZENECA
- Lubor Gaal, Ph.D., Head of External Innovation and Licensing, ALMIRALL
- Steven Gurney, Principal Associate and Patent Attorney, MARKS & CLERK
- Will James, Partner and Solicitor, MARKS & CLERK
- Carl Jessop, FRQA, Due Diligence Director, Business Development, ASTRAZENECA
- Cristiano Musso, Chief Business Officer, CIRCASSIA
- Mike Myers, Senior Director, Lilly Research Labs — Due Diligence, ELI LILLY
- Roland Pfeiffer, Ph.D., Head Commercial Development Europe, VIFOR PHARMA
Please fill in your name and email to receive the conference agenda of this event.
Conference Day One - Monday, February 26, 2018
Conference Dy Two - Tuesday, February 27, 2018
The agenda is available as PDF under downloads at the right side of the page.
Venue
The venue is not yet available for this event.
Follow this event to be informed when the venue is available and stay informed on other changes.
Who Should Attend
This conference is designed for representatives from pharmaceutical, medical device and biotechnology companies with responsibilities in the following areas:
- Due Diligence
- Business Development
- Strategic Alliance/Alliance Management
- Mergers and Acquisitions
- Licensing
- Intellectual Property and Patent Counsel
- Search and Evaluation
- Portfolio Management
- Scientific Assessment
- General Counsel/Corporate Counsel
- Legal and Regulatory Compliance
- Regulatory Affairs
- Research and Development
- Clinical Medicine
- Clinical Operations
- Lifecycle Management
This conference is also of interest to:
- Investment Banks
- Private Equity Firms
- Venture Capitalists
- Data Room Providers
- Due Diligence Consultants
- Law Firms
- Clinical Affairs and CRO Partners
- Regulatory Affairs and Compliance Partners
Venue
Radisson Blu Edwardian Portman Hotel22 Portman Square
Marylebone, London, UK W1H 7BG
At the Radisson Blu Portman Hotel, you’ll enjoy an inviting ambience and convenient location right in the heart of London. Just off Oxford Street, this stylish hotel is within minutes of key attractions such as the flagship John Lewis store, Madame Tussauds Wax Museum, Buckingham Palace and the West End theatres. The hotel is also a short walk from the Marble Arch and Bond Street Underground stations, both of which make it easy to travel around the city.
To make reservations, guests can call +44 207 208 6000, press option 1 and reference the group rate for 2502EXLALL.
The group rate is available until February 5, 2018. Please book your room early as rooms available at this rate are limited.
